ARRAY BIOPHARMA
Array BioPharma is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company partnered drugs are binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology), and tucatinib (partnered with Cascadian Therapeutics). The company is committed to providing therapies to patients. Array BioPharma was founded on 1998 and is headquartered in Boulder, Colorado.
ARRAY BIOPHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
1998-01-01
Address:
Boulder, Colorado, United States
Country:
United States
Website Url:
http://www.arraybiopharma.com
Total Employee:
101+
Status:
Closed
Contact:
303.381.6600
Email Addresses:
[email protected]
Total Funding:
412.1 M USD
Technology used in webpage:
Domain Not Resolving Google Maps IPv6 Google Maps API Microsoft IIS 7 Oracle Cloud ASP.NET 2.0
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Redmile Group
Redmile Group investment in Post-IPO Equity - Array BioPharma
Deerfield
Deerfield investment in Post-IPO Debt - Array BioPharma
Deerfield
Deerfield investment in Post-IPO Debt - Array BioPharma
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Venture Round - Array BioPharma
Official Site Inspections
http://www.arraybiopharma.com
- Host name: 147.154.27.36
- IP address: 147.154.27.36
- Location: Seattle United States
- Latitude: 47.6109
- Longitude: -122.3303
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98101
More informations about "Array BioPharma"
Array BioPharma - Wikipedia
Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019. See moreSee details»
Pfizer Completes Acquisition of Array Biopharma
Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development and …See details»
Pfizer to Acquire Array BioPharma
Jun 17, 2019 · Pfizer has agreed to acquire Array for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. The Boards of Directors of both companies have …See details»
Array BioPharma Inc. - LinkedIn
Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted...See details»
Array BioPharma - Crunchbase Company Profile
Array BioPharma is a biopharmaceutical company focused on the development and commercialization of targeted small molecule drugs. View contacts for Array BioPharma to access new leads and connect with decision-makers.See details»
Array BioPharma — Boulder Ventures Ltd.
Website: http://www.arraybiopharma.com Type of Company: Life Sciences Company Status: Realized Business: Array is a discovery research organization that sells chemicals and …See details»
Array Biopharma - Genomics.org
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat debilitating and life …See details»
Strengthening Pfizer’s R&D Engine and Oncology …
The acquisition of Colorado-based biotech Array BioPharma in July 2019 sets the stage for Pfizer to create a potentially industry-leading franchise for colorectal cancer alongside the company’s leadership in breast and prostate cancers. …See details»
Biotech Company Array To Be Acquired By Pfizer In $11.4 Billion …
Jun 17, 2019 · Dow Jones component Pfizer (PFE) is buying biotech company Array BioPharma (ARRY) in an $11.4 billion deal that reaps the rewards of two approved cancer treatments. The …See details»
Pfizer to buy Array BioPharma for $11 billion | CNN Business
Jun 17, 2019 · Pfizer agreed to spend $11 billion to buy Array BioPharma, a company that is developing small molecule medicines primarily to treat cancer. Array’s portfolio includes two …See details»
Pfizer to acquire US company Array BioPharma for …
Jun 18, 2019 · Pfizer has signed a definitive merger agreement to acquire US-based, commercial-stage biopharmaceutical company Array BioPharma. The acquisition is expected to build up Pfizer’s pipeline of oncology drugs. Credit: …See details»
Array BioPharma - Craft
Array BioPharma $173.77 m in annual revenue in FY 2018. See insights on Array BioPharma including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Array BioPharma - PitchBook
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its …See details»
Pfizer to Buy Cancer Drug Maker Array BioPharma for $10.64 Billion
Pfizer Inc. PFE 0.46% agreed to buy Array BioPharma Inc. ARRY -4.00% for $10.64 billion in cash, as one of the world’s biggest pharmaceutical companies seeks to expand its cancer …See details»
Array played with Pfizer's eagerness to land a deal on time—and …
Jul 1, 2019 · Array unveiled interim results from the phase 3 Beacon trial, showing a combination of Array’s Braftovi, Mektovi and the anti-EGFR drug Erbitux could significantly extend lives in …See details»
Array BioPharma Careers and Employment | Indeed.com
Sep 16, 2019 · Find out what works well at Array BioPharma from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for …See details»
Array BioPharma Announces FDA Approval of BRAFTOVI™ …
BOULDER, Colo., June 27, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI ™ …See details»
Array BioPharma And Pierre Fabre Announce Development And ...
Nov 16, 2015 · Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted …See details»
Pfizer to Acquire Array BioPharma - Business Wire
Jun 17, 2019 · Pfizer has agreed to acquire Array for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. The Boards of Directors of both companies have …See details»
Array BioPharma, Inc. (Array BioPharma, Inc.) - 药物管线_专利_临床 …
Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib may help treat patients with KIT-mutant …See details»